Anaemia management in chronic kidney disease rapid update 2011 : clinical guideline : methods, evidence, and recommendations

Chronic kidney disease (CKD) is not the most common cause of anaemia in the UK, but data from different sources suggest that nationally there are around 100,000 people with the combination of CKD and a low haemoglobin level. Anaemia in this context is important because it contributes significantly t...

Full description

Corporate Authors: National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain), National Institute for Health and Clinical Excellence (Great Britain), Royal College of Physicians of London
Format: eBook
Language:English
Published: London National Clinical Guideline Centre at the Royal College of Physicians c2011, 2011
Series:NICE clinical guidelines
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Chronic kidney disease (CKD) is not the most common cause of anaemia in the UK, but data from different sources suggest that nationally there are around 100,000 people with the combination of CKD and a low haemoglobin level. Anaemia in this context is important because it contributes significantly to the heavy symptom burden of CKD, and because it is potentially reversible with appropriate treatment, including erythropoietin. Erythropoietin is naturally produced by the kidneys and has been available in synthetic form for the treatment of anaemia of CKD since 1989, but it remains a fairly expensive product and its usage is not straightforward. Moreover, it will not necessarily be the only therapy required for optimal treatment. Against this background, the present guideline has been commissioned to address the appropriate management of anaemia of CKD for patients in the NHS.
Item Description:"February 2011."
Physical Description:1 online resource (PDF file (552 p.)) ill